Dose‐Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs

To address the most appropriate endogenous biomarker for drug–drug interaction risk assessment, eight healthy subjects received an organic anion transporting polypeptide 1B (OATP1B) inhibitor (rifampicin, 150, 300, and 600 mg), and a probe drug cocktail (atorvastatin, pitavastatin, rosuvastatin, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Daiki, Kimoto, Emi, Rago, Brian, Kondo, Yusuke, King‐Ahmad, Amanda, Ramanathan, Ragu, Wood, Linda S., Johnson, Jillian G., Le, Vu H., Vourvahis, Manoli, David Rodrigues, A., Muto, Chieko, Furihata, Kenichi, Sugiyama, Yuichi, Kusuhara, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158214/
https://www.ncbi.nlm.nih.gov/pubmed/31628668
http://dx.doi.org/10.1002/cpt.1695

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158214/
https://www.ncbi.nlm.nih.gov/pubmed/31628668
http://dx.doi.org/10.1002/cpt.1695

Ejemplares similares